Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 349 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Aortic Stenosis Clear all

Conditions: Hypertrophic Cardiomyopathy (HCM)
Interventions: myocardial contrast echo; Diagnostic Test
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Aortic Stenosis, Atrial Fibrillation New Onset, Heart Block
Interventions: TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473); Device
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Hypertrophic Cardiomyopathy
Interventions: Echo and myocardial contrast echocardiography perfusion imaging; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 19 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypertrophic Cardiomyopathy
Interventions: Ranolazine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Aortic Valve Stenosis
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hemorrhage
Interventions: aprotonin; epsilon aminocaproic acid; Drug
Lead sponsor: University of Rochester; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Aortic Stenosis, Hypoplastic Left Heart Syndrome
Interventions: Fetal Aortic Valvuloplasty; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Aortic Valve Stenosis
Interventions: TAVR with CENTERA THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 23
States / cities: Los Angeles, California • Stanford, California • Loveland, Colorado + 19 more

Conditions: Aortic Valve Stenosis
Interventions: SAPIEN 3 THV, Optimal Heart Failure Therapy; Device · Biological
Lead sponsor: Cardiovascular Research Foundation, New York; Other
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 46
States / cities: Chandler, Arizona • La Jolla, California • Los Angeles, California + 37 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: Diltiazem, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 5 Years to 39 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases, Ventricular Outflow Obstruction, Thrombosis
Interventions: Acetylsalicylic acid, Clopidogrel, Rivaroxaban; Drug
Lead sponsor: ECRI bv; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Aortic Stenosis
Interventions: AK-AVS; Device
Lead sponsor: AccurKardia, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Aortic Valve Stenosis, Aortic Stenosis, Aortic Valve Disease
Interventions: EmStop Embolic Protection System, Boston Scientific Sentinel; Device
Lead sponsor: EmStop Inc; Industry
Eligibility: 22 Years and older
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Thousand Oaks, California • Clearwater, Florida • New Orleans, Louisiana + 4 more

Conditions: Aortic Stenosis, Aortic Stenosis, Severe
Interventions: Edwards SAPIEN 3/SAPIEN 3 Ultra THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2038
U.S. locations: 50
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 43 more

Conditions: HOCM, Hypertrophic Obstructive Cardiomyopathy
Interventions: Mavacamten, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more

Conditions: Cardiomyopathy, Hypertrophic, Heart Hypertrophy
Interventions: Cyclosporine A; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aortic Valve Stenosis
Interventions: Direct Flow Medical, Commercially Available; Device
Lead sponsor: Direct Flow Medical, Inc.; Industry
Eligibility: Not listed
Enrollment: 878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: New York, New York • Columbus, Ohio • Charlottesville, Virginia

Conditions: Calcific Aortic Valve Disease
Interventions: Evogliptin, Placebo; Drug
Lead sponsor: REDNVIA Co., Ltd.; Industry
Eligibility: 35 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 21 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: Noncontrast echocardiography, Contrast Echocardiography, Cardiac magnetic resonance imaging; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Aortic Valve Stenosis, Aortic Valve Stenosis With Insufficiency, Regurgitation, Aortic Valve, Aortic Valve Incompetence
Interventions: Perceval S Aortic Heart Valve; Device
Lead sponsor: Sorin Group USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 21
States / cities: Opelika, Alabama • Tucson, Arizona • Aurora, Colorado + 16 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: pacemaker implantation, percutaneous transluminal septal ablation (PTSA); Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI); Device · Procedure
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 1,746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 65
States / cities: Phoenix, Arizona • Hollywood, California • La Jolla, California + 55 more

Conditions: Peripheral Vascular Disease, Peripheral Artery Disease, Carotid Stenosis, Aortic Aneurysm, Abdominal, Aortic Aneurysm, Thoracic, Amputation, Wound, Embolism and Thrombosis, Aortic Aneurysm
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New York, New York

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 1,453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more

Search by objective public record fields.

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry

Perfusion Imaging With Myocardial Contrast Echocardiography in HCM

Ranolazine for the Treatment of Chest Pain in HCM Patients

Defining Exercise Hemodynamics and Function After Transcatheter Aortic Valve Replacement (DEFINE-TAVR) Study.

Platelet Function And Aggregometry In Patients With Aortic Valve Stenosis

Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome

ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis

Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

ECG-based AI Screening for Cases of Undiagnosed Moderate-to-Severe Aortic Stenosis in the Primary Care Setting

CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material

PARTNER 3 Trial - Aortic Valve-in-Valve

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)

Transcatheter Aortic Valve Replacement System Pivotal Trial

A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

Assessment of Wall Thickness in Hypertrophic Cardiomyopathy

Perceval S Aortic Heart Valve Study- North America

A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Platelet Activity in Vascular Surgery for Thrombosis and Bleeding

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement